United States: Summary Of Trump Administration Drug Pricing And AKS Rulemakings And Implications For Life Sciences Companies And Health Care Providers - Foley Hoag LLP

United States: Summary Of Trump Administration Drug Pricing And AKS Rulemakings And Implications For Life Sciences Companies And Health Care Providers - Foley Hoag LLP

Mondaq

Published

On Friday, November 20, 2020, 60 calendar days prior to the inauguration of President-Elect Biden, the Trump administration released three rulemakings with significant implications for life sciences companies and healthcare providers.

Full Article